PF-06281192

PF-06281192 is a **humanized monoclonal antibody** targeting the extracellular domain of **human 5T4 antigen**, a fetal trophoblast glycoprotein expressed in various solid tumors[1][3][5]. It recognizes a conformational epitope on the 5T4 glycoprotein found on cancer cells. PF-06281192 is primarily known as the antibody component in the antibody-drug conjugate PF-06263507, where it is used as a targeting domain for delivery of cytotoxic agents. As an unconjugated antibody, PF-06281192 binds specifically to 5T4 but does not independently cause significant anti-tumor effects in preclinical models[1][5]; it mediates specific cell binding and internalization. PF-06281192 was developed by Pfizer for oncology indications, particularly advanced solid tumors expressing 5T4.

Brand names

PF-06281192PF06281192PF 06281192

Other names

huA1 monoclonal antibodyhuA-1 monoclonal antibodyhuA 1 monoclonal antibodyhumanized anti-5T4 IgG1 antibody